In line with these results, previous studies have shown that the potentiation of the CD200-CD200R1 signalling with a CD200R1 agonist has neuroprotective effects on different experimental models of brain diseases, such as the LPS or the human α-synuclein overexpression models of PD [78, 83], the experimental autoimmune encephalomyelitis model of multiple sclerosis [47] and experimental autoimmune uveoretinitis [13]. Here, CD200 is linked to experimental autoimmune encephalomyelitis.